Patrizia Porazzi

Dr. Patrizia Porazzi

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
PPPatrizia Porazzi
Patrizia Porazzi
DCD. Calebiro
D. Calebiro
FBF. Benato
F. Benato
Natascia TisoNatascia Tiso
Natascia Tiso
LPLuca Persani
Luca Persani

21 February 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ERE Rampazzo
E Rampazzo
LPLuca Persano
Luca Persano
FPF Pistollato
F Pistollato
Enrico MoroEnrico Moro
Enrico Moro
CFC Frasson
C Frasson
GBG Basso
G Basso
One of the biggest challenges in tumour research is the possibility to reprogram cancer cells towards less aggressive phenotypes. In this study, we reprogrammed primary Glioblastoma multiforme (GBM)-derived cells towards a more differentiated and less oncogenic phenotype by activating the Wnt pathway in a hypoxic microenvironment. Hypoxia usually correlates with malignant behaviours in cancer cells, but it has been recently involved, together with Wnt signalling, in the differentiation of embryonic and neural stem cells. Here, we demonstrate that treatment with Wnt ligands, or overexpression of β-catenin, mediate neuronal differentiation and halt proliferation in primary GBM cells. An hypoxic environment cooperates with Wnt-induced differentiation, in line with our finding that hypoxia inducible factor-1α (HIF-1α) is instrumental and required to sustain the expression of β-catenin transcriptional partners TCF-1 and LEF-1. In addition, we also found that Wnt-induced GBM cell differentiation inhibits Notch signalling, and thus gain of Wnt and loss of Notch cooperate in the activation of a pro-neuronal differentiation program. Intriguingly, the GBM sub-population enriched of cancer stem cells (CD133+ fraction) is the primary target of the pro-differentiating effects mediated by the crosstalk between HIF-1α, Wnt, and Notch signalling. By using zebrafish transgenics and mutants as model systems to visualize and manipulate in vivo the Wnt pathway, we confirm that Wnt pathway activation is able to promote neuronal differentiation and inhibit Notch signalling of primary human GBM cells also in this in vivo set-up. In conclusion, these findings shed light on an unsuspected crosstalk between hypoxia, Wnt and Notch signalling in GBM, and suggest the potential to manipulate these microenvironmental signals to blunt GBM malignancy.

29 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YLYong Gu Lee
Yong Gu Lee
PGPuneeth Guruprasad
Puneeth Guruprasad
GGGuido Ghilardi
Guido Ghilardi
RPRaymone Pajarillo
Raymone Pajarillo
CSChristopher Tor Sauter
Christopher Tor Sauter
MRMarco Ruella
Marco Ruella
Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of patients experience treatment failure. Resistance to apoptosis is a key feature of cancer cells, and it is associated with treatment failure. In 87 patients with NHL treated with anti-CD19 CART, we found that chromosomal alteration of B-cell lymphoma 2 (BCL-2), a critical antiapoptotic regulator, in lymphoma cells was associated with reduced survival. Therefore, we combined CART19 with the FDA-approved BCL-2 inhibitor venetoclax and demonstrated in vivo synergy in venetoclax-sensitive NHL. However, higher venetoclax doses needed for venetoclax-resistant lymphomas resulted in CART toxicity. To overcome this limitation, we developed venetoclax-resistant CART by overexpressing mutated BCL-2(F104L), which is not recognized by venetoclax. Notably, BCL-2(F104L)-CART19 synergized with venetoclax in multiple lymphoma xenograft models. Furthermore, we uncovered that BCL-2 overexpression in T cells intrinsically enhanced CART antitumor activity in preclinical models and in patients by prolonging CART persistence. Significance: This study highlights the role of BCL-2 in resistance to CART immunotherapy for cancer and introduces a novel concept for combination therapies—the engineering of CART cells to make them resistant to proapoptotic small molecules, thereby enhancing the therapeutic index of these combination therapies. This article is highlighted in the In This Issue feature, p. 2221

15 May 2013 in Molecular Genetics and Genomics
Verified
Journal Article
Open access
PDF file
Enrico MoroEnrico Moro
Enrico Moro
Andrea VettoriAndrea Vettori
Andrea Vettori
PPPatrizia Porazzi
Patrizia Porazzi
Marco SchiavoneMarco Schiavone
Marco Schiavone
ERElena Rampazzo
Elena Rampazzo
Francesco ArgentonFrancesco Argenton
Francesco Argenton
In the last years, we have seen the emergence of different tools that have changed the face of biology from a simple modeling level to a more systematic science. The transparent zebrafish embryo is one of the living models in which, after germline transformation with reporter protein-coding genes, specific fluorescent cell populations can be followed at single-cell resolution. The genetically modified embryos, larvae and adults, resulting from the transformation, are individuals in which time lapse analysis, digital imaging quantification, FACS sorting and next-generation sequencing can be performed in specific times and tissues. These multifaceted genetic and cellular approaches have permitted to dissect molecular interactions at the subcellular, intercellular, tissue and whole-animal level, thus allowing integration of cellular and developmental genetics with molecular imaging in the resulting frame of modern biology. In this review, we describe a new step in the zebrafish road to system biology, based on the use of transgenic biosensor animals expressing fluorescent proteins under the control of signaling pathway-responsive cis-elements. In particular, we provide here the rationale and details of this powerful tool, trying to focus on its huge potentialities in basic and applied research, while also discussing limits and potential technological evolutions of this approach.

20 February 2025 in Cancer Cell
Verified
Journal Article
Closed access
PPPatrizia Porazzi
Patrizia Porazzi
SNSiena Nason
Siena Nason
ZYZiqi Yang
Ziqi Yang
ACAlberto Carturan
Alberto Carturan
GGGuido Ghilardi
Guido Ghilardi
MRMarco Ruella
Marco Ruella

1 March 2016 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
TFTiziana de Filippis
Tiziana de Filippis
FMFederica Marelli
Federica Marelli
GNGabriella Nebbia
Gabriella Nebbia
PPPatrizia Porazzi
Patrizia Porazzi
SCSabrina Corbetta
Sabrina Corbetta
LPLuca Persani
Luca Persani
Article published by the Endocrine Society Article published by the Endocrine Society